| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 000 | 4 | NIH | 10/17/2024 | $0 |
| | 2025 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI172491 | Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens | 000 | 2 | NIH | 2/14/2025 | $0 |
| | 2025 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI162385 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum | 000 | 2 | NIH | 10/29/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $4,122,153 ) |
| | 2024 | 2024 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI170552 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | 000 | 4 | NIH | 5/17/2024 | $975,748 |
| | 2024 | 2024 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R44AI152788 | Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle | 000 | 4 | NIH | 3/27/2024 | $1,000,000 |
| | 2024 | 2024 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI162385 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum | 000 | 3 | NIH | 7/31/2024 | $1,039,551 |
| | 2024 | 2024 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 001 | 4 | NIH | 6/21/2024 | $1,363,709 |
| | 2024 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI172491 | Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens | 000 | 2 | NIH | 4/5/2024 | $0 |
| | 2024 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI172464 | Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), | 000 | 2 | NIH | 5/7/2024 | $0 |
| | 2024 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI138630 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses | 000 | 5 | NIH | 3/11/2024 | $0 |
| | 2024 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 000 | 3 | NIH | 10/13/2023 | $0 |
| | 2024 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R44HL123126 | Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT | 000 | 6 | NIH | 1/26/2024 | -$205,249 |
| | 2024 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R43AI152788 | Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle | 000 | 2 | NIH | 1/24/2024 | $0 |
| | 2024 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI155054 | PROTACS Against Nef as a Functional Cure for HIV Infection | 000 | 2 | NIH | 3/27/2024 | $0 |
| | 2024 | 2020 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R44CA156781 | Riluzole Prodrugs for Melanoma and ALS | 000 | 6 | NIH | 2/5/2024 | -$51,606 |
| | 2024 | 2020 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41EY030391 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | 000 | 1 | NIH | 2/15/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $5,001,928 ) |
| | 2023 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R44AI152788 | Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle | 000 | 3 | NIH | 4/7/2023 | $1,050,000 |
| | 2023 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI170552 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | 001 | 3 | NIH | 5/12/2023 | $990,011 |
| | 2023 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI172464 | Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), | 000 | 2 | NIH | 7/19/2023 | $292,428 |
| | 2023 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 000 | 3 | NIH | 7/25/2023 | $1,365,008 |
| | 2023 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI172491 | Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens | 000 | 2 | NIH | 6/12/2023 | $291,624 |
| | 2023 | 2023 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI138630 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses | 000 | 5 | NIH | 3/2/2023 | $1,012,857 |
| | 2023 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI170552 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | 000 | 2 | NIH | 4/26/2023 | $0 |
| | 2023 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R43AI152788 | Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle | 000 | 2 | NIH | 4/7/2023 | $0 |
| | 2023 | 2019 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R44HL123126 | Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT | 000 | 4 | NIH | 11/21/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $5,055,658 ) |
| | 2022 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI170552 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | 000 | 2 | NIH | 6/21/2022 | $1,050,000 |
| | 2022 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI172491 | Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens | 000 | 1 | NIH | 8/15/2022 | $306,500 |
| | 2022 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI172464 | Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), | 000 | 1 | NIH | 8/22/2022 | $306,500 |
| | 2022 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI162385 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum | 001 | 2 | NIH | 4/1/2022 | $300,000 |
| | 2022 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI138630 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses | 000 | 4 | NIH | 4/1/2022 | $1,015,449 |
| | 2022 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 002 | 2 | NIH | 8/8/2022 | $409,375 |
| | 2022 | 2022 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 001 | 2 | NIH | 7/8/2022 | $1,386,046 |
| | 2022 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI162385 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum | 000 | 1 | NIH | 4/1/2022 | $0 |
| | 2022 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 000 | 1 | NIH | 1/10/2022 | $309,543 |
| | 2022 | 2020 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R44CA156781 | Riluzole Prodrugs for Melanoma and ALS | 000 | 6 | NIH | 8/1/2022 | $0 |
| | 2022 | 2020 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41EY030391 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | 000 | 1 | NIH | 5/23/2022 | $0 |
| | 2022 | 2020 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41HL154852 | Soft LXR Agonists for Idiopathic Pulmonary Fibrosis | 000 | 1 | NIH | 11/28/2021 | $0 |
| | 2022 | 2019 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI138630 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses | 001 | 2 | NIH | 4/1/2022 | $0 |
| | 2022 | 2019 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI138630 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses | 000 | 2 | NIH | 2/28/2022 | $0 |
| | 2022 | 2018 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41DA047169 | Trigriluzole for the Treatment of Cocaine Addiction | 000 | 1 | NIH | 11/4/2021 | -$27,755 |
|
| Issue Date FY: 2021 ( Subtotal = $4,024,489 ) (Continued on the next page) |
| | 2021 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | U01AG068823 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | 000 | 1 | NIH | 6/23/2021 | $1,103,228 |
| | 2021 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R44HL123126 | Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT | 000 | 6 | NIH | 6/2/2021 | $999,965 |
| | 2021 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI162385 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum | 000 | 1 | NIH | 4/19/2021 | $306,500 |
| | 2021 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R41AI155054 | PROTACS Against Nef as a Functional Cure for HIV Infection | 000 | 2 | NIH | 6/16/2021 | $297,797 |
| | 2021 | 2021 | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 3805 OLD EASTON RD | DOYLESTOWN | PA | 18902-8400 | BUCKS | USA | R42AI138630 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses | 000 | 3 | NIH | 3/8/2021 | $1,017,000 |
|
